vs
Side-by-side financial comparison of Torrid Holdings Inc. (CURV) and INTEGRA LIFESCIENCES HOLDINGS CORP (IART). Click either name above to swap in a different company.
INTEGRA LIFESCIENCES HOLDINGS CORP is the larger business by last-quarter revenue ($434.9M vs $235.2M, roughly 1.8× Torrid Holdings Inc.). On growth, INTEGRA LIFESCIENCES HOLDINGS CORP posted the faster year-over-year revenue change (-1.7% vs -10.8%). INTEGRA LIFESCIENCES HOLDINGS CORP produced more free cash flow last quarter ($-5.4M vs $-6.6M). Over the past eight quarters, INTEGRA LIFESCIENCES HOLDINGS CORP's revenue compounded faster (8.6% CAGR vs -10.5%).
Torrid Holdings Inc. is an American women's retail chain formerly owned by Hot Topic. While it is still owned by Sycamore Partners, owners of Hot Topic, in 2015, the company branched off to become Torrid, LLC. The store offers plus-size clothing and accessories for women size 10-30. Torrid began operations in April 2001. The first location opened in the Brea Mall in Brea, California. As of 2024, Torrid has over 650 stores in operation across all states in the United States and some regions of...
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
CURV vs IART — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $235.2M | $434.9M |
| Net Profit | $-6.4M | — |
| Gross Margin | 34.9% | 50.8% |
| Operating Margin | 0.1% | 5.3% |
| Net Margin | -2.7% | — |
| Revenue YoY | -10.8% | -1.7% |
| Net Profit YoY | -438.2% | — |
| EPS (diluted) | $-0.06 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $235.2M | $434.9M | ||
| Q3 25 | $262.8M | $402.1M | ||
| Q2 25 | $266.0M | $415.6M | ||
| Q1 25 | $275.6M | $382.7M | ||
| Q4 24 | $263.8M | $442.6M | ||
| Q3 24 | $284.6M | $380.8M | ||
| Q2 24 | $279.8M | $418.2M | ||
| Q1 24 | $293.5M | $368.9M |
| Q4 25 | $-6.4M | — | ||
| Q3 25 | $1.6M | $-5.4M | ||
| Q2 25 | $5.9M | $-484.1M | ||
| Q1 25 | $-3.0M | $-25.3M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $8.3M | $-10.7M | ||
| Q2 24 | $12.2M | $-12.4M | ||
| Q1 24 | $-4.1M | $-3.3M |
| Q4 25 | 34.9% | 50.8% | ||
| Q3 25 | 35.6% | 51.5% | ||
| Q2 25 | 38.1% | 50.4% | ||
| Q1 25 | 33.6% | 50.8% | ||
| Q4 24 | 36.1% | 56.3% | ||
| Q3 24 | 38.7% | 52.6% | ||
| Q2 24 | 41.3% | 54.0% | ||
| Q1 24 | 34.5% | 56.1% |
| Q4 25 | 0.1% | 5.3% | ||
| Q3 25 | 3.9% | 2.9% | ||
| Q2 25 | 6.0% | -123.4% | ||
| Q1 25 | 1.3% | -4.0% | ||
| Q4 24 | 2.7% | 8.0% | ||
| Q3 24 | 7.2% | -2.1% | ||
| Q2 24 | 9.3% | -0.7% | ||
| Q1 24 | 1.4% | 1.1% |
| Q4 25 | -2.7% | — | ||
| Q3 25 | 0.6% | -1.3% | ||
| Q2 25 | 2.2% | -116.5% | ||
| Q1 25 | -1.1% | -6.6% | ||
| Q4 24 | -0.5% | — | ||
| Q3 24 | 2.9% | -2.8% | ||
| Q2 24 | 4.4% | -3.0% | ||
| Q1 24 | -1.4% | -0.9% |
| Q4 25 | $-0.06 | $-0.03 | ||
| Q3 25 | $0.02 | $-0.07 | ||
| Q2 25 | $0.06 | $-6.31 | ||
| Q1 25 | $-0.04 | $-0.33 | ||
| Q4 24 | $-0.01 | $0.25 | ||
| Q3 24 | $0.08 | $-0.14 | ||
| Q2 24 | $0.12 | $-0.16 | ||
| Q1 24 | $-0.03 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.2M | $263.7M |
| Total DebtLower is stronger | $276.4M | $726.6M |
| Stockholders' EquityBook value | $-206.5M | $1.0B |
| Total Assets | $402.9M | $3.6B |
| Debt / EquityLower = less leverage | — | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.2M | $263.7M | ||
| Q3 25 | $21.5M | $267.9M | ||
| Q2 25 | $23.7M | $253.6M | ||
| Q1 25 | $48.5M | $273.3M | ||
| Q4 24 | $44.0M | $273.6M | ||
| Q3 24 | $53.9M | $277.6M | ||
| Q2 24 | $20.5M | $296.9M | ||
| Q1 24 | $11.7M | $663.1M |
| Q4 25 | $276.4M | $726.6M | ||
| Q3 25 | $280.5M | $736.3M | ||
| Q2 25 | $284.5M | $745.9M | ||
| Q1 25 | $288.6M | $755.6M | ||
| Q4 24 | — | $760.5M | ||
| Q3 24 | — | $765.3M | ||
| Q2 24 | — | $770.2M | ||
| Q1 24 | — | $775.0M |
| Q4 25 | $-206.5M | $1.0B | ||
| Q3 25 | $-201.1M | $1.0B | ||
| Q2 25 | $-183.8M | $1.0B | ||
| Q1 25 | $-191.1M | $1.5B | ||
| Q4 24 | $-189.3M | $1.5B | ||
| Q3 24 | $-188.9M | $1.5B | ||
| Q2 24 | $-198.6M | $1.5B | ||
| Q1 24 | $-211.7M | $1.6B |
| Q4 25 | $402.9M | $3.6B | ||
| Q3 25 | $414.5M | $3.6B | ||
| Q2 25 | $451.4M | $3.7B | ||
| Q1 25 | $488.4M | $4.1B | ||
| Q4 24 | $493.0M | $4.0B | ||
| Q3 24 | $487.5M | $4.1B | ||
| Q2 24 | $479.7M | $4.1B | ||
| Q1 24 | $476.9M | $4.1B |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.49× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.9M | $11.8M |
| Free Cash FlowOCF − Capex | $-6.6M | $-5.4M |
| FCF MarginFCF / Revenue | -2.8% | -1.2% |
| Capex IntensityCapex / Revenue | 0.7% | 4.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.3M | $-31.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.9M | $11.8M | ||
| Q3 25 | $15.7M | $40.9M | ||
| Q2 25 | $-18.0M | $8.9M | ||
| Q1 25 | $12.0M | $-11.3M | ||
| Q4 24 | $-3.1M | $50.7M | ||
| Q3 24 | $40.8M | $22.5M | ||
| Q2 24 | $27.6M | $40.4M | ||
| Q1 24 | $9.0M | $15.8M |
| Q4 25 | $-6.6M | $-5.4M | ||
| Q3 25 | $14.6M | $25.8M | ||
| Q2 25 | $-20.6M | $-11.2M | ||
| Q1 25 | $10.2M | $-40.2M | ||
| Q4 24 | $-5.5M | $21.1M | ||
| Q3 24 | $37.7M | $-7.2M | ||
| Q2 24 | $20.6M | $10.7M | ||
| Q1 24 | $-1.7M | $291.0K |
| Q4 25 | -2.8% | -1.2% | ||
| Q3 25 | 5.6% | 6.4% | ||
| Q2 25 | -7.7% | -2.7% | ||
| Q1 25 | 3.7% | -10.5% | ||
| Q4 24 | -2.1% | 4.8% | ||
| Q3 24 | 13.2% | -1.9% | ||
| Q2 24 | 7.4% | 2.6% | ||
| Q1 24 | -0.6% | 0.1% |
| Q4 25 | 0.7% | 4.0% | ||
| Q3 25 | 0.4% | 3.8% | ||
| Q2 25 | 1.0% | 4.8% | ||
| Q1 25 | 0.6% | 7.6% | ||
| Q4 24 | 0.9% | 6.7% | ||
| Q3 24 | 1.1% | 7.8% | ||
| Q2 24 | 2.5% | 7.1% | ||
| Q1 24 | 3.7% | 4.2% |
| Q4 25 | — | — | ||
| Q3 25 | 10.05× | — | ||
| Q2 25 | -3.03× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.90× | — | ||
| Q2 24 | 2.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURV
| Apparel | $213.6M | 91% |
| Non Apparel | $12.3M | 5% |
| Other | $9.2M | 4% |
| Loyalty Program | $1.1M | 0% |
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
